25 completed, 7 terminated, 6 unknown, 2 withdrawn. 42 Phase 2, 10 Phase 3, 4 Phase 1.
Follow Embolism: new trials by email Literature Review of Embolism trials Research Report on Embolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vortosiran for VTE Prevention Vortosiran, Placebo - Venous Thromboembolism (VTE), Cancer | Phase 2 | Not yet recruiting | Ribocure Pharmaceuticals AB | 150 | 2026-10-01 | 2026-09-30 |
| Effect of iNO in Patients With Submassive and Massive PE inhaled nitric oxide (iNO) - Pulmonary Embolism, Pulmonary Embolism Subacute Massive | Phase 2 | Withdrawn | University of California, Los Angeles | 2026-06-01 | 2026-03-18 | |
| Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial TS23, Placebo - Pulmonary Embolism | Phase 2 | Active not recruiting | Translational Sciences, Inc. | 64 | 2023-05-24 | 2026-07-01 |
| Protect the Head to Head Study Emboliner Embolic Protection, Sentinel Cerebral Protection - Embolism | Phase 2 | Unknown | Emboline | 540 | 2023-05-04 | 2023-05-19 |
| Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events Rivaroxaban 20 MG [Xarelto], Aspirin 300mg, Acenocoumarol Oral Tablet - Venous Thromboembolism, Anticoagulant-induced Bleeding | Phase 2 / Phase 3 | Completed | Instituto Mexicano del Seguro Social | 58 | 2021-01-03 | 2022-08-25 |
| Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 Rivaroxaban, Standard Of Care (SOC) - COVID-19 | Phase 2 | Terminated | Charite University, Berlin, Germany | 111 | 2020-11-30 | 2022-01-12 |
| Low Dose Catheter Directed Thrombolysis for Acute Pulmonary Embolism Low dose alteplase, Unfractionated heparin, Infusion catheter - Pulmonary Embolism | Phase 2 | Unknown | University of Aarhus | 60 | 2020-03-10 | 2021-04-28 |
| DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE) DS-9231, Placebo - Pulmonary Embolism | Phase 2 | Withdrawn | Daiichi Sankyo | 2018-01-01 | 2018-12-24 | |
| Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma Enoxaparin - Venous Thromboembolism, Deep Vein Thrombosis | Phase 2 | Completed | University of Utah | 80 | 2017-11-15 | 2024-01-31 |
| Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery Fixed dose, Variable dose - Venous Thromboembolism, Deep Venous Thrombosis | Phase 2 | Completed | University of Utah | 295 | 2017-07-03 | 2020-09-16 |
| Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism DS-1040b, Placebo, Enoxaparin - Pulmonary Embolism, Thrombotic Disease | Phase 1 / Phase 2 | Completed | Daiichi Sankyo | 134 | 2016-06-23 | 2023-04-19 |
| Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery LMWH: Dalteparin, Placebo - Venous Thromboembolism, Lung Neoplasms | Phase 1 / Phase 2 | Completed | McMaster University | 102 | 2015-09-01 | 2018-09-18 |
| Enoxaparin Metabolism in Reconstructive Surgery Patients Enoxaparin - Venous Thromboembolism, Deep Venous Thrombosis | Phase 2 | Completed | University of Utah | 110 | 2015-03-01 | 2018-11-16 |
| Anticoagulation Length in Cancer Associated Thrombosis Low Molecular Weight Heparin (LMWH) - Cancer, Thrombosis | Phase 2 | Terminated | Cardiff University | 2 | 2013-12-01 | 2018-10-29 |
| Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study Enoxaparin 40 mg 2 hours before arm, Enoxaparin 40 mg 12 hours before arm - Morbid Obesity, Pulmonary Embolism | Phase 1 / Phase 2 | Unknown | Mansoura University | 700 | 2013-11-01 | 2015-04-08 |
| Nitric Oxide to Treat Pulmonary Embolism Inhaled Nitric Oxide, Sham - Pulmonary Embolism | Phase 2 | Completed | Indiana University | 78 | 2013-10-01 | 2018-10-03 |
| Clinical Study to Evaluate the Efficacy of Blood Purification Therapy on Cholesterol Crystal Embolism Liposorber LA-15 System - Cholesterol Embolism | Phase 2 | Unknown | Japan Community Health Care Organization Sendai Hospital | 35 | 2013-07-01 | 2016-07-04 |
| Diclofenac for Submassive PE Diclofenac, Placebo - Pulmonary Embolism | Phase 2 / Phase 3 | Terminated | Ministry of Health, Spain | 34 | 2012-05-01 | 2017-09-06 |
| Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism) prednisone, placebo - Cholesterol Embolism Systemic | Phase 2 | Terminated | University Hospital, Toulouse | 39 | 2011-06-01 | 2016-05-09 |
| Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer Rivaroxaban (Xarelto, BAY59-7939) - Venous Thrombosis, Deep Vein Thrombosis | Phase 2 | Completed | Bayer | 25 | 2009-05-01 | 2015-11-18 |
Showing 20 of 42. Sign in to see all of them.
Pulmonary Embolism (36) · Venous Thrombosis (18) · Venous Thromboembolism (15) · Thrombosis (6) · Embolism and Thrombosis (4) · Neoplasms (3) · Thromboembolism (3) · Atrial Fibrillation (2) · Cardiovascular Diseases (2) · Ventricular Dysfunction, Right (2) · Acquired Immunodeficiency Syndrome (1) · Ankle Fractures (1) · Atherosclerosis (1) · COVID-19 (1)
Vascular Diseases (41) · Cardiovascular Diseases (40) · Embolism and Thrombosis (38) · Lung Diseases (35) · Respiratory Tract Diseases (35) · Thrombosis (15) · Thromboembolism (14) · Heart Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Arrhythmias, Cardiac (2) · Fractures, Bone (2) · Infections (2) · Leg Injuries (2)
Enoxaparin (7) · Rivaroxaban (4) · Warfarin (4) · Dalteparin (3) · Fondaparinux (3) · Aspirin (2) · apixaban (2) · Acenocoumarol (1) · Diclofenac (1) · Embolic Protection Devices (1) · Endothelium-Dependent Relaxing Factors (1) · Heart-Lung Machine (1) · Heparin (1) · Heparin, Low-Molecular-Weight (1) · Magnetic Resonance Spectroscopy (1)
Daiichi Sankyo (3) · University of Utah (3) · Bayer (2) · Bristol-Myers Squibb (2) · GlaxoSmithKline (2) · University Of Perugia (2) · Abbott RDx Cardiometabolic (1) · Agen Biomedical (1) · Cardiff University (1) · Charite University, Berlin, Germany (1) · Crux Biomedical (1) · Emboline (1) · Indiana University (1) · Instituto Mexicano del Seguro Social (1) · Intermountain Health Care, Inc. (1)
United States (18) · Canada (9) · Austria (5) · Germany (5) · Italy (5) · Australia (4) · Denmark (4) · Israel (4) · Netherlands (4) · Poland (4) · Brazil (3) · France (3) · Hungary (3) · South Africa (3) · Spain (3)
Cecilia Becattini, MD (2) · Christopher Puccini, MD (2) · Giancarlo Agnelli, MD (2) · Alan Maisel, MD (1) · Anders Gabrielsen, MD, PhD (1) · Antoine Huart, MPD (1) · Asger Andersen, MD, PhD (1) · Bengt I Eriksson, MD (1)
PMID 30633959, PMID 33086312, PMID 16598645, PMID 18088349, PMID 18178417, PMID 19833379, PMID 19854398, PMID 20448094, PMID 21680946, PMID 22005573, PMID 22284935, PMID 22431865, PMID 22621626, PMID 23680957, PMID 24232703, PMID 26490434, PMID 28279428, PMID 28454823, PMID 29247809, PMID 29452956, PMID 29649055, PMID 31324209, PMID 33337539, PMID 33502773, PMID 34216189, PMID 34622445, PMID 35244208, PMID 35876829, PMID 36413425, PMID 38957026, PMID 9407246
1UM1HL113203-01A1 (1), 2004 (1), 2008 (1), 2015 (1), 2017 (1), R42HL086316 (1)